Biogen (BIIB) Expected to Announce Earnings on Tuesday

Biogen (NASDAQ:BIIB) is expected to be releasing its earnings data before the market opens on Tuesday, February 11th. Analysts expect Biogen to post earnings of $3.43 per share and revenue of $2.42 billion for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Biogen Stock Performance

Shares of Biogen stock opened at $141.35 on Monday. The business has a 50-day moving average price of $149.14 and a two-hundred day moving average price of $175.79. Biogen has a 1-year low of $139.71 and a 1-year high of $244.95. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The company has a market cap of $20.60 billion, a P/E ratio of 12.77, a PEG ratio of 1.65 and a beta of -0.08.

Analysts Set New Price Targets

BIIB has been the subject of a number of research reports. William Blair reissued an “outperform” rating on shares of Biogen in a research note on Monday, January 13th. Truist Financial reduced their price target on shares of Biogen from $302.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Piper Sandler downgraded shares of Biogen from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $315.00 to $138.00 in a report on Thursday, January 2nd. Barclays dropped their price objective on shares of Biogen from $190.00 to $180.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 31st. Finally, HC Wainwright restated a “buy” rating and issued a $300.00 target price on shares of Biogen in a report on Thursday, October 31st. Sixteen investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $228.80.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.